Birkenhäger, Tom K.

van Westrhenen, Roos

Background Medication side effects and limited efficacy are substantial problems in general and also in psychopharmaceuticals. Previous studies have shown that pharmacogenetic individual characteristics can be relevant. Aim To arrive at a responsible use of pharmacogenetics, exploiting its potential but also avoiding overdiagnosis. Method To provide an overview of the current status quo in the field of pharmacogenetics in psychiatry. Results The Dutch Association for Psychiatrists (NVvP) authorized a guideline 'Pharmacogenetics in Psychiatry' that is summarized. Also the current international guidelines and clinical implementation of pharmacogenetics are discussed. Conclusion For the time being, pharmacogenetics seems to be indicated only when patients have already experienced problems with psychopharmaca use, such as side effects and/or inefficacy. If genotyping is requested then generally CYP2C19 and CYP2D6 can be useful, as dosage recommendations are available in case of genetic variants

Current status quo on Pharmacogenetics in psychiatry

Abstract

Similar works

Full text

Available Versions

Maastricht University Research Portal